 |
|
An Aldose Reductase Inhibitor and Aminoguanidine Prevent Vascular Endothelial Growth Factor Expression in Rats With Long-term Galactosemia
Robert N. Frank, MD;
Rajesh Amin, MS;
Alexander Kennedy;
Thomas C. Hohman, PhD
Arch Ophthalmol. 1997;115(8):1036-1047.
Abstract
| |
Objective
To study the effects of an aldose reductase inhibitor (ARI-509, Wyeth-Ayerst, Princeton, NJ) and aminoguanidine (AMG), agents that have been reported to prevent or delay diabetic retinopathy, on retinal vascular abnormalities and the immunocytochemical expression in the retina of vascular endothelial growth factor (VEGF) in rats maintained for up to 2 years on a 50% galactose diet.
Methods
Albino rats were placed on a control diet, a diet containing 50% galactose, or the 50% galactose diet containing either ARI-509 or AMG. Treatment with ARI-509 or AMG was initiated at the beginning of the experiment or after 12 months of galactose feeding. After 22 to 24 months, the rats were killed and the retinal vasculature from half of one eye was isolated by trypsinelastase digestion for semiquantitative evaluation of retinal vascular lesions. The other half of the retina was prepared for immunocytochemistry and stained for the presence of VEGF, factor VIII, vimentin, and glial fibrillary acidic protein. Red blood cells, sciatic nerves, and a portion of the retina from the second eye were assayed for glucose, galactose, fructose, sorbitol, galactitol, and myo-inositol. Red blood cells were also assayed for galactosylated hemoglobin.
Results
Galactose-fed animals developed a vascular retinopathy characterized by severe cellular loss in the retinal capillaries and intensification of periodic acid-Schiff staining of the vascular basement membranes. Some animals also displayed dilation and hypercellularity of vessels in the posterior retina. These changes were substantially reduced in animals receiving ARI-509 from the beginning of the galactose diet, but were unaffected in all of the other treatment groups. None of the rats receiving ARI-509 or AMG treatment, whether initiated from the onset or after 12 months of galactosemia, demonstrated VEGF immunoreactivity. With the exception of the animals receiving ARI-509 from the beginning of the experiment, all of the galactose-fed animals developed dense cataracts within 6 weeks of the beginning of the galactose diet. Galactitol levels in animals receiving ARI-509 were 86% to 93% lower in red blood cells, retina, and sciatic nerve than those in the other galactosefed groups.
Conclusions
Although ARI-509 and AMG have different abilities to delay or prevent the diabetic-like retinopathy in galactosemic rats, even when substantial retinal microvascular acellularity occurs, both drugs prevent the immunocytochemical expression of VEGF. These results suggest that factors other than hypoxia may be responsible for VEGF expression in the retina, and that aldose reductase inhibitors and AMG have potential roles in preventing such expression and, thus, perhaps preventing retinal neovascularization.
Author Affiliations
From the Kresge Eye Institute, Wayne State University School of Medicine, Detroit, Mich.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Pharmacologic Manipulation of Sphingosine Kinase in Retinal Endothelial Cells: Implications for Angiogenic Ocular Diseases
Maines et al.
IOVS 2006;47:5022-5031.
ABSTRACT
| FULL TEXT
Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy
Yokoi et al.
Br J Ophthalmol 2005;89:673-675.
ABSTRACT
| FULL TEXT
Effect of PKC{beta} on Retinal Oxygenation Response in Experimental Diabetes
Luan et al.
IOVS 2004;45:937-942.
ABSTRACT
| FULL TEXT
Aldose Reductase Inhibitor Fidarestat Prevents Retinal Oxidative Stress and Vascular Endothelial Growth Factor Overexpression in Streptozotocin-Diabetic Rats
Obrosova et al.
Diabetes 2003;52:864-871.
ABSTRACT
| FULL TEXT
Termination of Experimental Galactosemia in Rats, and Progression of Retinal Metabolic Abnormalities
Kowluru and Koppolu
IOVS 2002;43:3287-3291.
ABSTRACT
| FULL TEXT
Glucose-Induced Activation of Glucose Uptake in Cells from the Inner and Outer Blood-Retinal Barrier
Busik et al.
IOVS 2002;43:2356-2363.
ABSTRACT
| FULL TEXT
Correction of Early Subnormal Superior Hemiretinal {Delta}PO2 Predicts Therapeutic Efficacy in Experimental Diabetic Retinopathy
Berkowitz et al.
IOVS 2001;42:2964-2969.
ABSTRACT
| FULL TEXT
Response of Capillary Cell Death to Aminoguanidine Predicts the Development of Retinopathy: Comparison of Diabetes and Galactosemia
Kern et al.
IOVS 2000;41:3972-3978.
ABSTRACT
| FULL TEXT
Glucose-Specific Regulation of Aldose Reductase in Human Retinal Pigment Epithelial Cells In Vitro
Henry et al.
IOVS 2000;41:1554-1560.
ABSTRACT
| FULL TEXT
Insulin-Induced Vascular Endothelial Growth Factor Expression in Retina
Lu et al.
IOVS 1999;40:3281-3286.
ABSTRACT
| FULL TEXT
Subnormal Retinal Oxygenation Response Precedes Diabetic-like Retinopathy
Berkowitz et al.
IOVS 1999;40:2100-2105.
ABSTRACT
| FULL TEXT
Retinopathy and Tissue Hexose in Drug-Treated Animals
Engerman et al.
Arch Ophthalmol 1998;116:543-544.
FULL TEXT
Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor
Stellmach et al.
Proc. Natl. Acad. Sci. USA 2001;98:2593-2597.
ABSTRACT
| FULL TEXT
|
